ICU Medical Appoints New CFO, Robert L. White

TL;DR

ICU Medical names Robert L. White as new CFO, starting Oct 7th. Expects $450k salary + bonus + $1M stock.

AI Summary

ICU Medical, Inc. announced on September 30, 2024, the appointment of Robert L. White as Chief Financial Officer, effective October 7, 2024. He will receive an annual base salary of $450,000 and a target annual bonus of 75% of his base salary. Additionally, Mr. White will be granted restricted stock units with a target value of $1,000,000, vesting over three years.

Why It Matters

The appointment of a new Chief Financial Officer is a significant leadership change that can impact the company's financial strategy and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key executive positions, especially CFO, can introduce uncertainty regarding future financial strategy and performance.

Key Numbers

• $450,000 — CFO Base Salary (Annual compensation for Robert L. White.)
• 75% — CFO Target Bonus (Potential bonus as a percentage of base salary for Robert L. White.)
• $1.0M — CFO Stock Grant (Target value of restricted stock units for Robert L. White.)

Key Players & Entities

• ICU Medical, Inc. (company) — Registrant
• Robert L. White (person) — Appointed Chief Financial Officer
• $450,000 (dollar_amount) — Annual base salary for new CFO
• 75% (dollar_amount) — Target annual bonus percentage
• $1,000,000 (dollar_amount) — Target value of restricted stock units for new CFO
• September 30, 2024 (date) — Date of report
• October 7, 2024 (date) — Effective date for new CFO

FAQ

Key Financial Figures

• $0.10 — ich registered Common stock, par value $0.10 per share ICUI The Nasdaq Stock Market

Filing Documents

• icui-20240930.htm (8-K) — 28KB
• 0000883984-24-000032.txt ( ) — 148KB
• icui-20240930.xsd (EX-101.SCH) — 2KB
• icui-20240930_lab.xml (EX-101.LAB) — 21KB
• icui-20240930_pre.xml (EX-101.PRE) — 12KB
• icui-20240930_htm.xml (XML) — 3KB

From the Filing

icui-20240930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) 09/30/2024 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-34634 33-0022692 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 951 Calle Amanecer , San Clemente , California 92673 (Address of principal executive offices) (Zip Code) ( 949 ) 366-2183 Registrant's telephone number, including area code N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common stock, par value $0.10 per share ICUI The Nasdaq Stock Market LLC (Global Select Market) Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of President On September 30, 2024, the Board of Directors of ICU Medical, Inc. (the "Company") appointed Mr. Daniel Woolson, 48, as President of the Company, effective immediately. Mr. Woolson has served as Corporate Vice President, General Manager – Infusion Systems since 2017. Mr. Woolson served as President, Respiratory Solutions for Becton Dickinson from March 2015 to November 2016. Prior to March 2015, Mr. Woolson held various roles at CareFusion and last served as Vice President/General Manager, Specialty Disposables. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ICU MEDICAL, INC. Date: October 2, 2024 By: /s/ Brian M. Bonnell Brian M. Bonnell Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR